Hyaluronate Protects From Benzalkonium Chloride-Induced Ocular Surface Toxicity

透明质酸可预防苯扎氯铵引起的眼表毒性

阅读:17
作者:Alexia Vereertbrugghen, Manuela Pizzano, Florencia Sabbione, Melina S Del Papa, Giselle Rodríguez, María Silvia Passerini, Jeremías G Galletti

Conclusions

SH mitigates BAK-associated ocular epithelial and neurotoxicity in a concentration-dependent manner. Translational relevance: Commercially available, high-concentration SH formulations may have added benefits in treating BAK-associated ocular surface toxicity.

Methods

Ocular surface epithelial cells from Balb/c mice were cultured with 0.1% to 0.4% SH and 0.001% to 0.01% BAK and their metabolic activity, viability, and wound repair capacity were assessed in vitro. Following a controlled corneal wound, re-epithelialization and recovery of epithelial barrier function and mechanosensitivity were measured in Balb/c mice treated with 0.4% SH 3 times/day and 0.01% BAK twice daily for 3 weeks. Nerve morphology was assessed by confocal microscopy of corneal whole mounts.

Purpose

The purpose of this study was to investigate the effect of sodium hyaluronate (SH) on benzalkonium chloride (BAK)-induced toxicity in the ocular surface epithelium and corneal nerves.

Results

Whereas BAK exposure reduced metabolic activity, viability, and wound repair ability of ocular epithelial cells in vitro, pretreatment with SH ameliorated BAK toxicity in a concentration-dependent manner. The highest SH concentration partially reversed the effects of 0.01% BAK in vitro and increased the corneal healing rate of BAK-exposed mice. Although all corneal wounds closed after 4 days, continuous SH treatment improved corneal barrier dysfunction 18 days after wounding and accelerated the recovery of corneal mechanical sensitivity to baseline levels in BAK-exposed mice. SH treatment also increased corneal nerve density in the wounded area after 3 weeks. Conclusions: SH mitigates BAK-associated ocular epithelial and neurotoxicity in a concentration-dependent manner. Translational relevance: Commercially available, high-concentration SH formulations may have added benefits in treating BAK-associated ocular surface toxicity.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。